Compare Amphastar Pharmaceuticals Inc (AMPH) vs Arko Corp. (ARKO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Arko Corp. — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Arko Corp. trades at $4.37 (market cap $527.27M). The key difference: Amphastar Pharmaceuticals Inc is the larger of the two by market cap, and Arko Corp. pays a 2.55% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | ARKO | |
|---|---|---|
Market Cap | $863.95M | $527.27M |
Sector | Health | Consumer Cyclical |
52-Week High | $30.81 | $8.64 |
52-Week Low | $16.87 | $3.82 |
Enterprise Value | $1.26B | $2.71B |
Dividend Yield | — | 2.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
ARKO Corp. (NASDAQ: ARKO) trades at $5.66, down 22.36% following weak Q2 2026 earnings that missed expectations. The stock shows bearish technical signals with oversold RSI readings near support at $5. Despite revenue declining to $7.64B in 2025, the company maintains positive cash flow and recently paid a $0.03 dividend. Analyst consensus remains cautious with 100% hold ratings amid concerns about consumer spending pressures.
The outlook remains challenging with declining revenues and thin profit margins (0.38% net margin), though management maintains 2026 EBITDA guidance. Key risks include competitive pressure in convenience retail and sensitivity to fuel price volatility. The current valuation at 0.08 P/S ratio may attract value investors if operational improvements materialize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Arko Corp.
ARKO Corp operates as a holding company. The company, through its subsidiaries, owns and operates convenience stores in the United States. Some of its regional store brands include Stop, Admiral, Apple Market, BreadBox, E-Z Mart, fas mart, Li'l Cricket, and Next Door Store. Its retail store offers hot food service, beverages, cigarettes & other tobacco products, candy, salty snacks, grocery, beer, and general merchandise. ARKO operates in three segments: Retail, Wholesale, and GPM Petroleum. The company derives the majority of its revenue from retail and wholesale distribution of fuel.
Read more on ARKO →
